ホーム › 非小細胞肺癌 › ネブラスカ州 › Lincoln
Lincoln、NEにおける非小細胞肺癌の臨床試験
Lincolnとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Nebraska Hematology-Oncology /ID# 272970, Lincoln
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第2/3相
- Nho - Revive Research Institute /ID# 277569, Lincoln
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Cancer Partners of Nebraska, Lincoln
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
被験者募集中第3相
- Nebraska Hematology-Oncology - Revive Research Institute LLC, Lincoln
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
被験者募集中第3相
- NHO Revive Research Institute, LLC ( Site 3218), Lincoln
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
被験者募集中第3相
- NHO Revive Research Institute LLC ( Site 0118), Lincoln
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Lincoln
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- NHO Revive Research Institute, LLC, Lincoln
- NHO Support Center, Lincoln
- Cancer Partners of Nebraska, Lincoln
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
被験者募集中第3相
- Cancer Partners of Nebraska, Lincoln
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
被験者募集中第2相
- Cancer Partners of Nebraska, Lincoln
Pan-tumor MRD Study
被験者募集中観察研究
- Cancer Partners of Nebraska, Lincoln
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Lincoln
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- NHO Revive Research Institute, Lincoln
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Lincoln
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
被験者募集中第2相
- Nebraska Hematology-Oncology, Lincoln
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
被験者募集中第2相
- USA14-0, Lincoln
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Lincolnにおける他の研究
- 心不全8件の研究
- 肺がん7件の研究
- 冠動脈疾患5件の研究
- 統合失調症4件の研究
- 乳がん4件の研究
- 大腸癌4件の研究
- 肥満症4件の研究
- 筋萎縮性側索硬化症3件の研究
- がん（全種類）3件の研究
- 多発性骨髄腫3件の研究
- 悪性黒色腫3件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。